Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary) ; Nintedanib; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms PRAISE
- Sponsors FibroGen
- 30 Sep 2019 Results presented in a FibroGen Media Release.
- 30 Sep 2019 According to a FibroGen media release, data published in The Lancet Respiratory Medicine.
- 04 Feb 2019 Status changed from active, no longer recruiting to completed.